title: Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses.
abstract: We previously reported that DNA vaccination was able to elicit cellular immune responses and partial protection against Chlamydia trachomatis infection. However, DNA immunization alone did not generate immune responses or protection as great as that induced by using live organisms. In this study, we evaluated the immunologic effects of a combinational vaccination approach using C. trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) DNA priming followed by boosting with immune-stimulating complexes (ISCOM) of MOMP protein (MOMP ISCOM) for protection of BALB/c mice against MoPn lung infection. Substantially better protection to challenge infection was observed in mice given combinational vaccination compared with mice given MOMP ISCOM immunization alone, and the protection approximated that induced by live organisms. Enhanced protection was correlated with stronger delayed-type hypersensitivity, higher levels of gamma interferon production, and increased immunoglobulin A antibody responses in lung homogenates. The results indicate that DNA priming followed by ISCOM protein boosting may be useful in designing a fully protective chlamydial vaccine.
authors.affiliation: Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E OW3.
authors.forename: Z
authors.initials: Z
authors.lastname: Dong-Ji
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.forename: C
authors.initials: C
authors.lastname: Shen
authors.forename: H
authors.initials: H
authors.lastname: Lu
authors.forename: A
authors.initials: A
authors.lastname: Murdin
authors.forename: R C
authors.initials: RC
authors.lastname: Brunham
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000517:prevention & control*; D002692:Chlamydia trachomatis / Q000276:immunology*; D005260:Female; D006968:Hypersensitivity, Delayed; D016882:ISCOMs / Q000276:immunology*; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000097:blood; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D011014:Pneumonia / Q000517:prevention & control; D018272:Porins; D013154:Spleen / Q000166:cytology / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D016882:ISCOMs; D007070:Immunoglobulin A; D018272:Porins; D016753:Interleukin-10; C071677:omp1 protein, Chlamydia trachomatis; D007371:Interferon-gamma